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Volume 59, Number 6S Abstracts 79Sdeep venous thrombosis (DVT) or pulmonary embolism
(PE). Inferior vena cava (IVC) ﬁlter was placed in eight.
In group 1, 17 limbs were treated with OST (ligation
and stripping/excision of saphenous or lateral embryonic
veins); in group 2, 10 limbs were treated with RFA. Phle-
bectomies were performed in both groups, with thigh
tourniquet in 21 limbs. Technical success of saphenous/
lateral vein ablation was 100% in group 1 and 90% in
group 2. There was no DVT or PE; none had thrombus
extension into deep veins after RFA. Perioperative compli-
cations occurred in 19% (three of 16) in group 1
(bleeding, wound dehiscence, paresthesia) and in 20%
(two of 10, P ¼ NS) in group 2 (bleeding, thrombophle-
bitis). Follow-up averaged 15 months (range, 1-57
months). No patients reported worsening of symptoms,
and none required repeat interventions. Marked improve-
ment in symptoms was reported in 55% in group 1 and in
25% in group 2 (P ¼ NS). All patients continued to wear
elastic garments.
Conclusions: Surgical and endovenous treatment in
select patients with KTS is safe and can be performed
with low rate of complications. More data are needed
to justify IVC ﬁlter placement. Although symptomatic
varicose veins can be removed, residual symptoms due
to persistent venous insufﬁciency are frequent. Lifelong
elastic support is warranted.
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Objectives: Inferior vena cava (IVC) ﬁlter placement
is not without risk. It has been associated with puncture
site bleeding, venous thrombosis, as well as ﬁlter migra-
tion and perforation. The objective of this study was to
assess our experience with open operative explantation
of IVC ﬁlters.
Methods: After IRB approval, patients were identiﬁed
from case logs that had transabdominal IVC ﬁlter removal
between 1994 and 2013. Patient demographics, thrombo-
embolic risk proﬁle, clinical history, operative indication,
and outcomes were recorded for each case.
Results: Eighteen patients (9 male; mean age, 49.6
years) were identiﬁed. IVC ﬁlters (4 permanent, 8 retriev-
able, 6 unknown) were deployed for a combination of
signiﬁcant thromboembolic events (n ¼ 16), after trauma
(n ¼ 3), or after failure of anticoagulation therapy
(n ¼ 2). Ten patients had retrievable ﬁlters that were
not removed percutaneously due to ﬁlter strut perforation
into surrounding pericaval tissue. Seven patients subse-
quently presented with abdominal/back pain, hematuria,
or sepsis. Midline laparotomy was used for explantation in11 patients during oncologic resections. A subcostal inci-
sion (n ¼ 5) was used for planned explantation alone.
One patient had robotic-assisted laparoscopic removal
and another had an open transjugular removal. Caval
venotomy was primarily closed (n ¼ 15) or patched
with bovine pericardium (n ¼ 2). No complications
attributed to ﬁlter removal were identiﬁed in the postop-
erative period. One patient died of advanced malignancy,
and the other 17 patients remain well (mean follow-up,
618 days).
Conclusions: Filter strut caval perforation remains
the most signiﬁcant indication for transabdominal removal.
Filter removal is often considered incidentally during onco-
logic resection. Although operative explantation still remains
infrequent, our series suggests that it may be performed
safely without signiﬁcant postoperative complications.
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Objectives: To determine the difference in durability
of venous ablation in patients on warfarin anticoagulation
compared with those without alteration in their coagula-
tion pathway.
Methods: Data were collected from a single-center
institution: NYU Medical Center using International
Classiﬁcation of Diseases, Ninth Revision codes for pa-
tients who had undergone radiofrequency or laser venous
ablation between April 2011 and May 2013. Covidian
CF7-7-60 2nd generation VNUS catheters were used
for radiofrequency ablation and EVLT NeverTouch kits
by Angiodynamics for laser ablation. Patients being
concomitantly treated with warfarin were selected for
study. Follow-up with venous duplex ultrasound imaging
was performed at 1 week, 6 months, and then yearly to
check for thrombus extension from the superﬁcial to
the deep venous system and document occlusion status
of the treated veins.
Results: There were 72 patients: 40 male (55.5%) and
32 female (44.5%), with 94 limbs and 97 procedures per-
formed. Average follow-up time was 142.5 days (range,
7-636 days). Fifty-four procedures (55.7%) were radiofre-
quency ablations, and 43 (44.3%) were laser ablations.
Four veins (4.1%) recanalized within the follow-up time
period: one was a radiofrequency ablation (1.9%), and
three were laser (7.0%). Two of these occurred #1 week,
and the other two between 6 and 12 months after the pro-
cedure. Nine patients (12.5%) in our study were on aspirin
and one (1.3%) was on Plavix, all of whom had successful
venous ablations without recanalization within the
follow-up time period. None of the patients in our study
experienced complications.
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quency of recanalization after endovenous ablation while
on warfarin is not worse compared with that described in
the literature. The population size of this subset was
small, but it appears antiplatelet agents also had no sig-
niﬁcant impact on incidence of recanalization. Thus,
we believe it is safe to perform endovenous ablation
on systemically anticoagulated patients with no appre-
ciable negative impact on short-term durability or
effectiveness.
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Objectives: Hypoxia-inducible factors (HIFs) are
transcription factors that transcribe a spectrum of genes
during hypoxia and other stress conditions. In particular,
the HIF-2a subtype is more stable than HIF-1a in mild
hypoxia and plays an essential role in vascular remodeling
by transcribing angiogenic factors. We previously
observed that silencing of Int6, a hypoxia-independent
regulator of HIF-2a protein, led to neoangiogenesis by
facilitating HIF-2a activity in normoxia. The aim of cur-
rent study was to test the hypothesis that silencing of
Int6 in muscle may enhance the recovery of blood ﬂow
in ischemic limbs.
Methods: We used a small interfering RNA (siRNA)
plasmid designed to inhibit the Int6 gene, and assessed
the inﬂuence of Int6 silencing on the gene and protein
expression of mouse myoblasts quantitative RT-PCR and
Western blotting. In vivo, BALB/c mice were randomized
to treatment and control groups. After unilateral femoral
artery ligation, the Int6 siRNA plasmid was injected into
the muscle near the ligation site. Tissue damage and loss
of limb function were scored for 28 days. Serial measure-
ments of limb perfusion were also obtained by laser
Doppler perfusion imaging. A random siRNA plasmid
was given to the control group.
Results: Silencing of Int6 in cultured myoblasts led to
stabilization of HIF-2a protein, accompanied by upregula-
tion of angiogenic genes, including basic ﬁbroblast growth
factor and platelet-derived growth factor-B compared with
the control (P < .05). In a mouse model of hind limb
ischemia, intramuscular injection of the Int6 siRNA
plasmid signiﬁcantly enhanced perfusion (P < .05 at days
7 and 14) and functional recovery (P < .05 at days 7,
14, and 21) of damaged limbs.Conclusions: Silencing of Int6 in muscle led to
enhanced perfusion and functional recovery in ischemic
limbs. Int6 may serve as a therapeutic target to control
angiogenesis in ischemic diseases.
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Objectives: Mesenchymal stem cells (MSCs) have
been shown to improve regeneration of injured tissues in
vivo. Several in vitro studies and animal models have
demonstrated improvement in MSCs paracrine effects un-
der hypoxic conditions. Moreover, several studies sug-
gested that the pro B-type natriuretic peptide (pro-BNP)
could be involved in the stimulation of postischemic
vascular regeneration. The purpose of this study was to
investigate the effect of critical limb ischemia, in a human
model, on in situ adipose-derived mesenchymal stem cells
(ADMSCs) and to determine whether serum levels of N-
terminal pro-BNP correlate with ADMSCs counts and
associated paracrine effects.
Methods: Lipoaspirate samples of $10 mL were
collected from ischemic limbs (ischemic group) and
compared with control samples (without ischemia).
MSCs were characterized by frequency, viability, differenti-
ation potential, cytokines expression, and cell surface
markers. Serum NT pro-BNP was measured as well.
Results: MSCs counts were ninefold to 10-fold higher
in patients with ischemic limbs (mean 7952 6 542 MSC/
mL) than controls (mean 790 6 65 MSC/mL). Pro-BNP
levels (range, 1878-4757 pg/mL) were approximately
eightfold to 26-fold higher than in age- and sex-matched
controls. Furthermore, there were positive correlations be-
tween pro-BNP levels and MSCs counts in the ischemic
group.
Conclusions: Patients with critical limb ischemia
(CLI) have higher levels of pro-BNP and MSCs counts
than controls. Increased levels of pro-BNP and MSCs
counts can be considered humoral and cellular surrogates
of ischemia and hypoxia in patients with CLI. This sup-
ports recent studies that suggest that the increase produc-
tion of peripheral BNP may be a stem cells-mediated
response to stimulate angiogenesis in the ischemic skeletal
muscles.
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